Literature DB >> 18804399

Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.

Kazuko Hasegawa1, A Jon Stoessl, Teruo Yokoyama, Hisayuki Kowa, Zbigniew K Wszolek, Saburo Yagishita.   

Abstract

BACKGROUND: Since the causative gene linked to PARK8 parkinsonism was identified as LRRK2, LRRK2 gene mutations have been found to occur in about 4% of patients with hereditary Parkinson disease (PD); this percentage is even higher in certain populations. Moreover, no clear clinical differences between PARK8-linked parkinsonism and sporadic PD have been identified. Neuropathologic findings have been diverse in PARK8 parkinsonism, but few of the clinicopathologic examinations have been performed in the same family tree. We aimed to describe PET and neuropathologic findings in members of the same family tree with PARK8 parkinsonism.
METHODS: We conducted PET of 2 subjects and neuropathologically examined 8 subjects in the same family from the Sagamihara district, the original source of PARK8-linked parkinsonism (I2020T mutation).
RESULTS: The results of the PET scans were virtually identical to those seen in sporadic PD. The neuropathologic study results showed pure nigral degeneration with no Lewy bodies in 6 cases. One case, however, showed the presence of Lewy bodies and was similar neuropathologically to conventional PD with Lewy bodies. Another case had multiple system atrophy pathology.
CONCLUSIONS: Our study of PARK8-linked parkinsonism affecting several members of the same pedigree shows that the same gene mutation can induce diverse neuropathologies, even if the clinical picture and PET findings are virtually identical.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18804399      PMCID: PMC2702757          DOI: 10.1016/j.parkreldis.2008.07.010

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  22 in total

1.  Lrrk2 and Lewy body disease.

Authors:  Owen A Ross; Mathias Toft; Andrew J Whittle; Joseph L Johnson; Spiridon Papapetropoulos; Deborah C Mash; Irene Litvan; Mark F Gordon; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

2.  Biochemical and pathological characterization of Lrrk2.

Authors:  Benoit I Giasson; Jason P Covy; Nancy M Bonini; Howard I Hurtig; Matthew J Farrer; John Q Trojanowski; Vivianna M Van Deerlin
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

3.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

Authors:  John R Adams; Hinke van Netten; Michael Schulzer; Edwin Mak; Jessamyn Mckenzie; Audrey Strongosky; Vesna Sossi; Thomas J Ruth; Chong S Lee; Matthew Farrer; Thomas Gasser; Ryan J Uitti; Donald B Calne; Zbigniew K Wszolek; A Jon Stoessl
Journal:  Brain       Date:  2005-08-04       Impact factor: 13.501

4.  G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Authors:  Carles Gaig; María José Martí; Mario Ezquerra; Maria Jesús Rey; Adriana Cardozo; Eduardo Tolosa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-08       Impact factor: 10.154

5.  The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems.

Authors:  M Inoue; S Yagishita; M Ryo; K Hasegawa; N Amano; M Matsushita
Journal:  Acta Neuropathol       Date:  1997-06       Impact factor: 17.088

6.  [A big family of paralysis agitans (author's transl)].

Authors:  H Nukada; H Kowa; T Saitoh; Y Tazaki; S Miura
Journal:  Rinsho Shinkeigaku       Date:  1978-10

7.  (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

Authors:  S Orimo; E Ozawa; S Nakade; T Sugimoto; H Mizusawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

8.  Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions.

Authors:  Justus C Dächsel; Owen A Ross; Ignacio F Mata; Jennifer Kachergus; Mathias Toft; Ashley Cannon; Matt Baker; Jennifer Adamson; Mike Hutton; Dennis W Dickson; Matthew J Farrer
Journal:  Acta Neuropathol       Date:  2006-12-07       Impact factor: 17.088

9.  Western Nebraska family (family D) with autosomal dominant parkinsonism.

Authors:  Z K Wszolek; B Pfeiffer; J R Fulgham; J E Parisi; B M Thompson; R J Uitti; D B Calne; R F Pfeiffer
Journal:  Neurology       Date:  1995-03       Impact factor: 9.910

10.  Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation.

Authors:  D S Goldstein; R Imrich; E Peckham; C Holmes; G Lopez; C Crews; J Hardy; A Singleton; M Hallett
Journal:  Neurology       Date:  2007-07-11       Impact factor: 9.910

View more
  42 in total

1.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

2.  Lower Vitamin B12 Level at Multiple System Atrophy Diagnosis Is Associated With Shorter Survival.

Authors:  Stuart J McCarter; Elizabeth A Coon; Rodolfo Savica; Erik K St Louis; James H Bower; Eduardo E Benarroch; Paola Sandroni; Phillip Low; Wolfgang Singer
Journal:  Mov Disord       Date:  2020-04-22       Impact factor: 10.338

Review 3.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

Review 4.  CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.

Authors:  Fatemeh Safari; Gholamreza Hatam; Abbas Behzad Behbahani; Vahid Rezaei; Mazyar Barekati-Mowahed; Peyman Petramfar; Farzaneh Khademi
Journal:  Cell Mol Neurobiol       Date:  2019-11-26       Impact factor: 5.046

Review 5.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

6.  First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.

Authors:  Andreas Puschmann; Elisabet Englund; Owen A Ross; Carles Vilariño-Güell; Sarah J Lincoln; Jennifer M Kachergus; Stephanie A Cobb; Anna-Lena Törnqvist; Stig Rehncrona; Håkan Widner; Zbigniew K Wszolek; Matthew J Farrer; Christer Nilsson
Journal:  Parkinsonism Relat Disord       Date:  2011-12-06       Impact factor: 4.891

7.  Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease.

Authors:  Hiroshi Ichinose; Ken-Ichi Inoue; Shinobu Arakawa; Yuki Watanabe; Hiroki Kurosaki; Shoko Koshiba; Eldbjorg Hustad; Masahiko Takada; Jan O Aasly
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

Review 8.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 9.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

10.  Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions.

Authors:  Elisa A Waxman; Jason P Covy; Irene Bukh; Xiaojie Li; Ted M Dawson; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2009-07       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.